12th week of 2010 patent applcation highlights part 22 |
Patent application number | Title | Published |
20100074869 | Multifunctional Cytokines - The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof. | 2010-03-25 |
20100074870 | Probiotic infant products - The present invention is directed to an infant formula or children's nutritional product comprising a protein source, a fat source, a carbohydrate source, and | 2010-03-25 |
20100074871 | Probiotic infant products - The present invention is directed to an infant formula or children's nutritional product comprising a protein source, a fat source, a carbohydrate source, and | 2010-03-25 |
20100074872 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING GASTROINTESTINAL, SKIN, AND NASAL MICROBIOTA - The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant | 2010-03-25 |
20100074873 | Live bacteria product - A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The liquid carrier is sufficiently devoid of moisture so that substantially all of the bacteria will remain in a dormant state for several months or until applied to the target host. The liquid carrier has a moisture content of less than one percent and preferably has a moisture content of less than one-tenth of one percent. The carrier contains mineral oil and a suspension agent and may also include an adsorbent. The suspension agent may be polymers such as synthetic polymers. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH of the target host then activates the bacteria. | 2010-03-25 |
20100074874 | SYNTHETIC MULTI-LAYER STRUCTURES COMPRISING BIOPOLYMER FIBRES - The invention relates to a method for the in vitro preparation of a synthetic multi-layer structure comprising biopolymer fibers, wherein the biopolymer fibers in each layer are unidirectionally and uniformly oriented, which comprises successive polymerisation of layers of a biopolymer fiber forming solution in the presence of a magnetic field, wherein the fiber orientation in at least one layer differs from that in at least one of its superior and/or inferior layer according to an angle alpha. The invention also relates to a biological tissue-like multi-layer structure comprising the synthetic multi-layer structure and cells inoculated therein, such as an orthogonal multi-layer collagen and/or fibrin tissue-like cornea, and the method for its preparation. The invention may be used for preventing or treating a damaged tissue, or for creating a model for biological testing, such as pharmacotoxicity testing. | 2010-03-25 |
20100074875 | COMPOSITION CONTAINING HUMAN UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELL FOR INDUCING DIFFERENTIATION AND PROLIFERATION OF NEURAL PRECURSOR CELLS OR NEURAL STEM CELLS TO NEURAL CELLS - A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases. | 2010-03-25 |
20100074876 | CALCIUM PHOSPHATE DELIVERY VEHICLES FOR OSTEOINDUCTIVE PROTEINS - A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed. | 2010-03-25 |
20100074877 | COMPOSITION FOR IMPROVING SKIN QUALITY AND A PROCESS FOR PREPARING THE SAME - The present invention relates to a composition including, as active substance, a mixture of at least one polyunsaturated fatty acid, different from polyunsaturated fatty acid derived from milk, polyphenols, milk proteins and lactic bacteria, and the composition having a water content of at least 50% by weight; and wherein the polyunsaturated fatty acid presents an increased bioavailability compared with the one of the polyunsaturated fatty acid alone. | 2010-03-25 |
20100074878 | Probiotic bacterium: lactobacillus fermentum - Variant of the bacterium | 2010-03-25 |
20100074879 | SKIN AGENT FOR EXTERNAL USE AND COSMETIC AGENT INCLUDING UBIQUINONE DERIVATIVE OR SALT THEREOF AND METHOD USING THE SAME - A skin agent for external use and a cosmetic agent are provided, by transdermal administration of which expected actions and effects of ubiquinone derivatives, salts thereof, ubiquinones and ubiquinols are effectively obtained. | 2010-03-25 |
20100074880 | POLYETHYLENE GLYCOL DERIVATIVE - The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150. | 2010-03-25 |
20100074881 | MULTIPLE NEBULIZER SYSTEMS - A device for administering two or more therapeutic agents simultaneously, comprising two or more nebulizers and a single connector linking the nebulizers to a nebulizer mouthpiece. Also provided is a method of administering two or more therapeutic agents simultaneously, comprising administering the therapeutic agents simultaneously with the device of the present invention to a subject in need thereof. | 2010-03-25 |
20100074882 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS - Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and/or directly or indirectly antagonizing calcineurin or constitutively active calcineurin (and combinations thereof), to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment. | 2010-03-25 |
20100074883 | Devices and methods for repair of larynx, trachea and other fibrocartilaginous tissues - Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal. | 2010-03-25 |
20100074884 | INHIBITION OF NEURONAL DAMAGE - Materials and Methods for inhibiting neuronal damage are provided herein. In particular, materials and methods for inhibiting neuronal damage associated with pathological action of extracellular ATP are provided herein. | 2010-03-25 |
20100074885 | Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase - Provided are combinations, compositions and kits containing a immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are methods for subcutaneous administration of immune globulin whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same IG-treatable disease or condition. | 2010-03-25 |
20100074886 | CCR2 ANTAGONISTS FOR TREATMENT OF FIBROSIS - Anti-MCP-1/CCR2 antagonist therapy is provided for the control or reversal of fibrosis related diseases, including, e.g., but not limited to MCP-1/CCR2 antagonist therapy for the modulation of profibrotic markers associated with fibrotic processes including collagen matrix deposition and alveolar collapse. | 2010-03-25 |
20100074887 | Methods for Treating and Diagnosing Fibrotic and Fibroproliferative Diseases - The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. | 2010-03-25 |
20100074888 | ANIMAL HAVING MODIFICATION IN MGAT2 GENE - It is an object to provide a gene-modified non-human animal having inactivated MGAT2 gene and a gene-modified non-human animal cell, which are useful for the search of the function of MGAT2 in vivo. It is another object to provide a method for screening of a compound capable of inhibiting the activity of MGAT2 and a compound capable of inhibiting the activity of MGAT2. It is further another object to provide a method for detecting a disease induced by abnormal lipid metabolism based on the expression level or activity of MGAT2. A method for screening of a compound by using a gene-modified non-human mammal having the artificially inhibited expression of MGAT2 gene and a cell thereof enable to prevent or treat a disease induced by abnormal lipid metabolism. Also a screening of a compound capable of inhibiting or enhancing the function of MGAT2 enables to prevent or treat a disease induced by abnormal lipid metabolism. | 2010-03-25 |
20100074889 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: | 2010-03-25 |
20100074890 | METHODS FOR IDENTIFYING HCV PROTEASE INHIBITORS - The present invention provides methods for identifying compounds useful as HCV protease inhibitors. | 2010-03-25 |
20100074891 | Sclerostin and the inhibition of Wnt signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 2010-03-25 |
20100074892 | Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin - The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2010-03-25 |
20100074893 | ECM-Complex Antibody Compositions and Methods of Use - The invention provides isolated anti-ECM-complex antibodies that bind to ECM-complexes. The invention also encompasses compositions comprising an anti-ECM-complex antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-ECM-complex antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-ECM-complex antibodies. The invention encompasses a method of producing the anti-ECM-complex antibodies. Other aspects of the invention are a method of detecting an ECM-complex expressing cancer, a method of inhibiting growth of an ECM-complex-expressing tumor, and a method of alleviating or treating an ECM-complex-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-ECM-complex antibody to the mammal. | 2010-03-25 |
20100074894 | PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES DIRECTED AGAINST THE HERV-W ENVELOPE - A pharmaceutical composition that contains, as an active ingredient, at least one antibody directed against the HERV-W envelope protein, except for any antibody specifically directed against the binding site between said env protein and the hASCT1 or hASCT2 receptor. | 2010-03-25 |
20100074895 | METHOD FOR DETECTING AND CONTROLLING CANCER - Methods are provided for treating cancer metastasis by administering a therapeutic composition targeting a kinase substrate cascade. | 2010-03-25 |
20100074896 | ANTAGONISTS OF PGE2 EP3 RECEPTORS - PGE2 EP3 receptors affect injury size following cerebral ischemia and induced excitotoxicity. Treatment with selective EP3 antagonists decreases infarct size. In addition, such antagonists can reduce lesions caused by N-methyl-D-aspartic acid-induced acute excitotoxicity. Similarly, genetic deletion of EP3 provides protection against N-methyl-D-aspartic acid-induced toxicity. PGE2, by stimulating EP3 receptors, can contribute to the toxicity associated with cyclooxygenase and that antagonizing this receptor can be used therapeutically to protect against stroke- and excitotoxicity-induced brain damage. | 2010-03-25 |
20100074897 | Methods and Compositions related to HIF-1 alpha - Disclosed are compositions and methods related to HIF-1α. | 2010-03-25 |
20100074898 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure relates to compounds of formula (I): | 2010-03-25 |
20100074899 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2010-03-25 |
20100074900 | PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2010-03-25 |
20100074901 | HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel human anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2010-03-25 |
20100074902 | METHODS FOR HUMAN ALLOGRAFTING - A method of preparing a human recipient for a graft from a human which includes: administering donor peripheral blood progenitor cells to the recipient, and providing a minimally ablative. | 2010-03-25 |
20100074903 | NOVEL ANTIBODY FORMULATION - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 2010-03-25 |
20100074904 | SPECIFIC ACTIVATION OF A REGULATORY T CELL AND ITS USE FOR TREATMENT OF ASTHMA, ALLERGIC DISEASE, AUTOIMMUNE DISEASE, GRAFT REJECTION AND FOR TOLERANCE INDUCTION - The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction. | 2010-03-25 |
20100074905 | METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2010-03-25 |
20100074906 | Antibodies Specific for Varicella Zoster Virus - The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection. | 2010-03-25 |
20100074907 | Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists - This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist. | 2010-03-25 |
20100074908 | Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention. | 2010-03-25 |
20100074909 | Combinations for the treatment of cancer - This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer. | 2010-03-25 |
20100074910 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment - The present disclosure provides methods for treating cancer in a patient in need of such treatment, the method includes prequalifying a patient's therapeutic treatment by performing a molecular imaging procedure to the patient using a labeled biomarker specific for a cancer target at the tumor site; and administering a therapeutic effective amount of a compound comprising a targeting agent linked to a chemotherapeutic or a targeting agent linked to an antibody. Embodiments of the present invention also include compounds and compositions for using such methods. | 2010-03-25 |
20100074911 | VACCINE NEBULIZERS - The invention provides a method of selecting or optimising a nebuliser device to be used to deliver a vaccine comprising selecting a nebuliser capable of producing a plurality of vaccine particles having the following particle droplet size distribution:
| 2010-03-25 |
20100074912 | HILA-A24-BINDING KEF-DERIVED PEPTIDE - An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma. | 2010-03-25 |
20100074913 | Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres - This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres. | 2010-03-25 |
20100074914 | DNA vaccine comprising CTGF-encoding DNA construct and applications thereof - The present invention provides a DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises a CTGF-encoding sequence and a HPV sequence selected from an E6-encoding sequence, an E7-encoding sequence, or a combination thereof. In addition, the present invention also provides a pharmaceutical composition and a method of generating said DNA vaccine. | 2010-03-25 |
20100074915 | CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES - Chimeric Influenza virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide, a neuraminidase polypeptide and optionally a hemagglutinin polypeptide. Preferred methods of generation include expression in insect cells. | 2010-03-25 |
20100074916 | AVIAN INFLUENZA VACCINE - H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines. | 2010-03-25 |
20100074917 | METHOD FOR PREVENTING DISEASES IN WEANED PIGLET - An object of the present invention is to provide a method for preventing diseases in weaned piglets, which relieves the stress of postweaning piglets and enhances the immunostimulating ability in order to prevent the death due to colibacillosis such as edema disease in postweaning piglets and to increase the rate of raising. | 2010-03-25 |
20100074918 | VACCINE - The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventor discloses that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem. | 2010-03-25 |
20100074919 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-03-25 |
20100074920 | PEPTIDE VACCINE FOR INFLUENZA VIRUS - The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes 5 for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza. | 2010-03-25 |
20100074921 | CARRIER - The present invention is directed to providing a carrier which can transport a compound to a gut-associated lymphoid tissue efficiently without being degraded or digested. For that purpose, the carrier contains a coccoid cell of a gastric mucosa-damaging spiral bacterium. Preferably, the carrier is orally administered. By making this carrier carry an antigen and orally administering it, a local or a systemic immunological reaction to the antigen can be induced. | 2010-03-25 |
20100074922 | Pneumococcal polysaccharide conjugate vaccine - The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent | 2010-03-25 |
20100074923 | PURIFICATION OF BACTERIAL ANTIGENS - Presented are methods of isolation of pili and pilus-like structures from Gram-positive bacteria including | 2010-03-25 |
20100074924 | MEMBRANE PROTEIN SM29 OF SCHISTOSOMA MANSONI AND USES THEREOF FOR TREATING AND DIAGNOSING SCHISTOSOMIASIS - The present invention relates to a Sm29 membrane protein and to an immunoenzymatic assay (diagnosis) capable of detecting specific IgG antibodies against the Sm29 protein present in the serum of schistosomiasis patients, the use of Sm29 as a vaccine in the prevention of schistosomiasis and the use of Sm29 in the treatment of allergic diseases. The immunoenzymatic assay is capable of detecting specific IgG antibodies against Sm29 present in the sera of individuals with schistosomiasis. Support-adsorbed Sm29 is reacted with the test sera. After incubation with the conjugate, the reaction is developed with a solution composed of the enzyme substrate used in the conjugate (chro-mogen). After the development of the reaction, it is paralyzed with the acid solution and read in a spectrophotometer. The vaccine using Sm29 is capable of reducing the number of adult worms in vaccinated animals in 31.2% (without adjuvant); 51% and 56.7% (with adjuvant). Vaccination is also capable of reducing the number of parasite eggs in the intestine in 37.6% and 60%, and the number of granulomas in the liver of the host in 48% and 61%. Vaccination is done by using 10-50 μg of recombinant Sm29 with or without the use of a sub-cutaneously-applied adjuvant. After 15 days, two booster doses are applied with a 15-day interval containing 10-50 μg of recombinant Sm29 with or without the use of an adjuvant. The stimulation of mononuclear cells of the peripheral blood of asthmatic patients shows that Sm29 is capable of inducing a high production of IL-10 the innate immune system cells, thus evidencing its potential use as a therapeutic in the treatment of allergic diseases. | 2010-03-25 |
20100074925 | ANTIGEN SPECIFIC MULTI EPITOPE VACCINES - The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET. | 2010-03-25 |
20100074926 | MODULES, NEW ASSEMBLAGE KITS AND NEW ASSEMBLES FOR THE CONTROLLED RELEASE OF SUBSTANCES - A module which is destroyed in the presence of water solution, composed of a compressed powdery mixture, the said powdery mixture comprising a matrix building component, suitable to release an optionally included active substance into a surrounding aqueous liquid, and one or more tabletting aids chosen from the group consisting of lubricants, glidants, and anti-adherent agents, the said module being provided with particular male topological features allowing its connection to a corresponding female module, giving raise to an assembly that can be safely handled on industrial scale, wherein, in the composition of the male module, the percentage ratio between the tabletting aid and the matrix building component is comprised between 1:2.5 and 1:999. The module can be employed to convey pharmaceuticals, nutraceuticals, agrochemicals or other active principles to the intended site of action. | 2010-03-25 |
20100074927 | DELIVERY OF THERAPEUTIC COMPOUNDS VIA MICROPARTICLES OR MICROBUBBLES - Microparticle carriers, particularly protein-encapsulated microbubbles, are used to deliver antiproliferative drugs to target sites in a subject. In particular, antirestenotic drugs are delivered to areas of vascular injury for treatment or prevention of hyperproliferative disease, e.g. stenosis, in blood vessels; and antineoplastic drugs are targeted to tumor sites. | 2010-03-25 |
20100074928 | Cosmetic Composition - Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average surface area from 30 m | 2010-03-25 |
20100074929 | ADMINISTRATION OF AGENTS MIMICKING DOPACHROME TAUTOMERASE (TRP-2) ACTIVITY FOR PROTECTING HAIR FOLLICLE MELANOCYTES - Agents mimicking DOPAchrome tautomerase activity are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair. | 2010-03-25 |
20100074930 | METHOD OF MAKING POLYMER HOLLOW PARTICLES WITH CONTROLLABLE HOLES IN THEIR SURFACES - A method for making a hollow polymer particle having a single, substantially circular opening in its surface. | 2010-03-25 |
20100074931 | USE OF A HIGHLY EMULSIFIED SILICONE OIL (HES) FOR THE PRODUCTION OF A MEDICAMENT - The invention relates to the use of a silicone oil emulsion comprising 0.01-85 wt. % of silicones, particularly polydimethylsiloxanes, 0.01-90 wt. % of hydrophobic emulsifier that has an HLB value ranging from 1 to 7 and/or a hydrophilic emulsifier that has an HLB value ranging from 7 to 14 and/or 0.01-90 wt. % of a mixture of one or more hydrophobic and hydrophilic emulsifiers having an HLB value ranging from 1 to 14, and 0.1-99 wt. % of biocompatible saline solution, for producing a medicament as such or in combination with other medicaments or carrier materials for treating septic infections triggered by bacterial, viral, parasitic, and fungal causative agents or diseases in animals and humans caused by traumas. | 2010-03-25 |
20100074932 | ANTIMICROBIAL COMPOSITIONS CONTAINING GALLIUM - Antimicrobial compositions may provide varying release kinetics for the active ions in the compositions due to the different water solubilities of the ions, allowing antimicrobial release profiles to be tailored for a given application and providing for sustained antimicrobial activity over time. According to some embodiments, the antimicrobial compositions may comprise polymer compositions containing colloids including salts of one or more oligodynamic metals, such as gallium. The antimicrobial compositions may be produced, for example, by mixing a solution of the salts of one or more oligodynamic metals with a polymer solution or dispersion and precipitating a colloid of the metal salts by addition of other salts to the solution which react with the metal salts. The compositions can be incorporated into articles or can be employed as a coating on articles such as medical devices including, for example, catheters, implants, and endotracheal tubes. The coatings may be on all or part of a surface. | 2010-03-25 |
20100074933 | Cell And Enzyme Compositions For Modulating Bile Acids, Cholesterol and Triglycerides - The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier. | 2010-03-25 |
20100074934 | MEDICAL IMPLANTS WITH A COMBINATION OF COMPOUNDS - Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers. | 2010-03-25 |
20100074935 | RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided. | 2010-03-25 |
20100074936 | Repair of larynx, trachea, and other fibrocartilaginous tissues - Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal. | 2010-03-25 |
20100074937 | POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS - An aromatic polyanhydride comprising a repeating unit having the structure | 2010-03-25 |
20100074938 | IMMOBILISED BIOLOGICAL ENTITIES - There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which entity is covalently attached to said surface through a link comprising a 1,2,3-triazole. | 2010-03-25 |
20100074939 | HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-03-25 |
20100074940 | LINEAR POLYESTERAMIDES FROM AMINOPHENOLIC ESTERS - The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by | 2010-03-25 |
20100074941 | Absorbable, permeability-modulated barrier composites and applications thereof - Absorbable barrier composites are designed for modulated gas and water permeability depending on clinical use and are formed of at least two physicochemically distinct components, one of which is a film adjoined to a knitted mesh and/or electrostatically spun, non-woven fabric. Depending on the physicochemical properties of the barrier composite, it can be used in neurological and urinogenital surgical procedures as well as tissue engineering and/or as physical barriers to prevent adhesion formation following several types of surgical procedures. | 2010-03-25 |
20100074942 | DEVICE AND METHOD FOR INTRAOCULAR DRUG DELIVERY - Intraocular devices having a drug delivery construct attached thereto, and methods for using the devices for intraocular drug delivery and the treatment and/or prevention of conditions. | 2010-03-25 |
20100074943 | MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME - An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc. This transdermal absorption preparation comprises a medicinal composition for transdermal absorption in which an active ingredient selected from morphine and salts thereof is blended in such an amount as corresponding to the saturation solubility or more in an active ingredient-holding vehicle having fluidity at a temperature around the human skin surface temperature and at least a portion of the active ingredient is held in a crystalline form, characterized in that, in the case where a preparation obtained from the above-described medicinal composition for transdermal absorption is applied to the uninjured skin of the back of a white rabbit having been shaven with electrical clippers for 72 hours, the available amount of the active ingredient per single dose of the preparation is from 10 mg to 400 mg in terms of morphine base, and the plasma concentrations of the active ingredient 24 hours and 48 hours after the application of the preparation under the above-described conditions are each at least 40 ng/mL in terms of morphine base, and so on. | 2010-03-25 |
20100074944 | Transdermal Tobacco Alkaloid Reservoir Patch - The invention relates to a tobacco alkaloid patch ( | 2010-03-25 |
20100074945 | MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES - Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8 | 2010-03-25 |
20100074946 | PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether) | 2010-03-25 |
20100074947 | Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form. | 2010-03-25 |
20100074948 | METHOD OF PRODUCING FAST DISSOLVING TABLETS - A method of producing a fast-melt tablet comprises the steps of forming a mixture of components, the mixture comprising at least one fast dissolving sugar alcohol, at least one disintegrant or osmotic agent, and at least one an active component, blending the mixture for a period of time, and directly compressing the blended mixture at a compression force of typically between 5 and 2O kN to form the fast-melt tablet. The process of the invention does not involve any granulation step, thereby making the process more energy efficient and cost effective. The fast dissolving sugar alcohol is selected from the group comprising: mannitol; sorbitol; erythritol; xylitol; lactose; dextrose; and sucrose, and comprises at least 50%, preferably at least 60%, and more preferably at least 70%, of the tablet (w/w). The active component is suitably provided in the form of microparticles or microcapsules having an average diameter of less than 125 microns. Also described are directly compressed fast dissolving type tablets obtainable by the process of the invention. The tablets typically are flat-faced. | 2010-03-25 |
20100074949 | Pharmaceutical composition and administration thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 2010-03-25 |
20100074950 | ANTI-DIABETIC COMBINATIONS - A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor and a slow release biguanide is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide is also provided. | 2010-03-25 |
20100074951 | CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS - Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body. | 2010-03-25 |
20100074952 | TASTED MASKED VETERINARY SOLID COMPOSITIONS - The present invention relates to the supply and production of an animal medicine consisting of a substrate in pellet or tablet form, which is attractive to livestock and domestic animals, in which fine-grained particles of a neutral-tasting, physiologically compatible, solid carrier material are embedded, which is characterised in that said fine-grained particles of carrier material have an average diameter of 0.09 to 0.8 mm and are coated with an active substance from veterinary medicine, and said active substance layer is covered with a protective layer of a physiologically compatible polymer matrix, and to the production of this animal medicine. It also relates to the usage of said double-coated, fine-grained particles of carrier material in the production of a preparation for veterinary medicine. | 2010-03-25 |
20100074953 | Methods for intiating in situ formation of hydrogels - Methods for initiating formation of hydrogels in situ from a gellable composition and an initiator where the initiator is provided as a solid article or is contained in a solution infused to the intended site of formation of the hydrogel. | 2010-03-25 |
20100074954 | ADSORBENT FOR ORAL ADMINISTRATION - An adsorbent for oral administration, characterized by comprising a spherical activated carbon, wherein a diameter is 0.01 to 1 mm, a specific surface area determined by Langmuir's adsorption equation is 1000 m | 2010-03-25 |
20100074955 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity - The present invention relates to an active substance combination comprising at least one compound with 5-HT | 2010-03-25 |
20100074956 | FORMATION OF HYDROGEL IN THE PRESENCE OF PEROXIDASE AND LOW CONCENTRATION OF HYDROGEN PEROXIDE - In a process of forming a hydrogel from a mixture comprising hydrogen peroxide (H | 2010-03-25 |
20100074957 | INTRAOCULAR FORMULATION - Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies. | 2010-03-25 |
20100074958 | METHODS AND COMPOSITIONS FOR TARGETING FENESTRATED VASCULATURE - Targeting of a fenestrated vasculature at a body site by micro or nanoparticles can be increased by using particles that have a radius substantially equal to a critical radius of a normal vasculature at the body site. The particles can be used for treating or monitoring a physiological condition responsible for the fenestrated vasculature. A method of improving an ability of micro or nanoparticles to target fenestrated blood vessels in a body site by selecting particles from a population of the micro or nanoparticles, where the selected particles have a radius that permits enhanced delivery into the fenestrated blood vessels. | 2010-03-25 |
20100074959 | LIPID GROWTH FACTOR FORMULATIONS - The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels. | 2010-03-25 |
20100074960 | HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS OF MAKING AND USING SAME - Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2010-03-25 |
20100074961 | POLYMER MICROSPHERES/NANOSPHERES AND ENCAPSULATING THERAPEUTIC PROTEINS THEREIN - This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore. | 2010-03-25 |
20100074962 | DEGRADATION OF PRION PROTEIN AND REDUCED PRION INFECTIVITY BY EARTHWORM HOMOGENATES - Methods for the degradation of prion proteins are described. Items that may be contaminated with prions are treated with earthworm-derived extracts to degrade prion proteins and reduce their infectivity in animals. Methods of using an earthworm-derived protein extract for treating foodstuffs and surfaces to inhibit or disable prion infectivity are disclosed. Also disclosed are methods for treating medical instruments, tools used to butcher animals, and laboratory equipment. | 2010-03-25 |
20100074963 | Red Palm Oil and Fish Oil Wound Dressing - A cosmeceutically acceptable formulation as a wound dressing including red palm oil and a triglyceride, preferably fish oil, preferably derived from salmon. Another aspect of this disclosure is providing a mixture of red palm oil and very long chain (>C | 2010-03-25 |
20100074964 | Super brown cream - A topical cream for use in healing hemorrhoids, tumid veins, damaged capillaries, rectal bleeding and rectal discomfort. The cream comprises propolis that has been extracted from material formed by honeybees, such propolis is present in the cream in a predetermined amount. Olive oil is blended with such propolis in a predetermined ratio to form such topical cream. | 2010-03-25 |
20100074965 | COSMETIC COMPOSITION COMPRISING A METEORITE EXTRACT, AND USE OF THE EXTRACT AS COSMETIC AGENT SUITABLE FOR STIMULATING THE DIFFERENTIATION OF HUMAN KERATINOCYTES - The present invention relates to a cosmetic composition comprising a meteorite extract. The present invention also relates to methods of using the extract as a cosmetic agent suitable for stimulating the differentiation of human keratinocytes. | 2010-03-25 |
20100074966 | Gaseous Mixture Containing O2 and N2O For Preventing Or Reducing Hyperalgesia - The invention relates to a gaseous mixture containing oxygen and nitrous oxide in a nitrous oxide proportion of between 5 and 15 vol. %, that can be used for producing a drug for preventing or reducing hyperalgesia in human beings or animals, in particular a post-operation opioid-induced hyperalgesia. | 2010-03-25 |
20100074967 | Aqueous disinfectants and sterilants including transition metals - The present invention is drawn to disinfectant or sterilant compositions, which are human safe, e.g., food grade or food safe. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001 wt % to 25 wt % of a peroxide. Additionally, from 0.001 ppm to 50,000 ppm by weight of a transition metal based on the aqueous vehicle content can also be present. The composition can be substantially free of aldehydes. Alternatively or additionally, the transition metal can be in the form of a colloidal transition metal. | 2010-03-25 |
20100074968 | AGENT AND METHOD FOR TREATING CANCER COMPRISING STRONTIUM, AMINO ACID(S) AND MINERAL AGENT(S) - The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer. | 2010-03-25 |